Application Software

Below are the top mid-cap application software stocks on the NYSE and the NASDAQ in terms of return on equity. The trailing-twelve-month return on equity at Manhattan Associates (NASDAQ: MANH) is 43.50%. Manhattan Associates' revenue for the same period is $469.30 million. The trailing-twelve-month...

Moving up: Prothena Corp (NASDAQ: PRTA) - up 24% - Reported clinical data to be presented at International Symposium on Amyloidosis. Morgan Stanley raised the price target on the stock from $35.00 to $53.00. First Solar (NASDAQ: FSLR) - up 20% - Sees FY2014 EPS $2.20-2.60; sees sales $3.70B-4.0B...

Below are the top application software stocks on the NASDAQ in terms of return on equity. The trailing-twelve-month return on equity at NIC (NASDAQ: EGOV) is 46.60%. NIC's revenue for the same period is $245.70 million. The trailing-twelve-month return on equity at Cadence Design Systems (NASDAQ...

Below are the top application software stocks on the NASDAQ in terms of earnings estimate for the next quarter. OpenText (NASDAQ: OTEX) is estimated to post earnings of $1.33 per share in the September quarter. OpenText's trailing-twelve-month revenue is $1.32 billion. F5 Networks (NASDAQ: FFIV...

Manhattan Associates (Nasdaq: MANH), today announced that ACCO Brands (NYSE: ACCO), one of the world's largest suppliers of branded office products, has chosen to implement Manhattan's Warehouse Management (WMS) and Supply Chain Intelligence (SCI) solutions in its Halesowen (UK) warehouse, and...

Benchmark has released a research report stating that Manhattan Associates, Inc. (NASDAQ: MANH) reported a favorable quarter last night driven by a good large deal performance. In the report, Benchmark commented, “Adjusted EPS and license revenue beat our estimates, though total revenue of $85.6...

Benchmark reiterates its Hold rating on Manhattan Associates (NASDAQ: MANH) as the company is set to report on 4Q11 after market close tonight. Benchmark says, "We expect the Company to deliver total revenue and license revenue relatively in line with our estimates of $85 million and $16 million...

Voxware and Manhattan Associates (NASDAQ: MANH) announced that Voxware has become a member of Manhattan's Value Partner program. Prior to this, in July 2011, the two companies entered into an agreement making Manhattan Associates a reseller of Voxware's voice solutions. These agreements facilitate...

Benchmark lowers its rating on Manhattan Associates (NASDAQ: MANH) to Hold from Buy primarily due to its current valuation limiting near-term upside potential. Benchmark says, "MANH's shares have appreciated 40% ytd (vs. -8% for the broader software sector) and, since our April 2010 upgrade, are...

Analysts at Mizuho downgraded Boston Scientific Corporation (NYSE: BSX) from “buy” to “neutral.” BSX's shares closed at $5.21 yesterday. Boston Scientific's trailing-twelve-month ROA is 3.10%. The Benchmark Company downgraded Manhattan Associates Inc (NASDAQ: MANH) from “buy” to “hold.” MANH's...

Thursday, December 22, 2011 This is your Benzinga news summary and trader's outlook covering headlines from overnight and today's pre-market session. • • After the Great Depression it took 25 years for the stock market to recover fully, to the point it'd been at before the crash. Benzinga's Top...

The Benchmark Company has downgraded Manhattan Associates (NASDAQ: MANH) from Buy to Hold.

Vermont-based A.N. Deringer, Inc., one of the nation's largest privately-held customs brokerage 3PLs, is reaping the rewards of a successful implementation of Manhattan Associates' (Nasdaq: MANH) Manhattan SCALE suite in 10 warehouses over a 12 month period. Since the implementation, Deringer has...

Price: $42.50Forward P/E: 18Earnings Growth: 61%Projected Sales Growth: 12%Market Cap: $880 million Why It's Featured: Earnings should be up by more than 60% this year; zero debt; high return on equity.Danger Zones: Nearing full valuation. Manhattan Associates (NASDAQ: MANH) develops and provides...

Rodman & Renshaw has published a research report on Alnylam Pharmaceuticals (NASDAQ: ALNY) after the company presented positive Phase I data for ALN-TTR01. In the report, Rodman & Renshaw writes, "All of the five patients receiving the drug at this concentration showed lowering of serum...